

CITATION REPORT

List of articles citing

Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis

DOI: 10.2165/00003088-200544060-00001
Clinical Pharmacokinetics, 2005, 44, 551-70.

Source: <https://exaly.com/paper-pdf/39421291/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
178	Who will benefit from antiresorptive treatment (bisphosphonates)?. 2005 , 19, 965-73		5
177	How much bone for the buck? The importance of compliance issues in economic evaluations of bisphosphonates. 2005 , 5, 369-71		1
176	Once-monthly ibandronate. 2005 , 4, 381-7; discussion 389-90		3
175	Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. 2006 , 7, 508-14		272
174	Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. 2006 , 66, 2031-58		68
173	Bisphosphonate actions: physical chemistry revisited. <i>Bone</i> , 2006 , 38, 613-6	4.7	66
172	Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. <i>Journal of Dental Research</i> , 2007 , 86, 1022-33	8.1	191
171	Prolonged bisphosphonate release after treatment in children. 2007 , 356, 1075-6		147
170	Osteonecrosis of the jaw and bisphosphonates: a comparison with white phosphorus, radium, and osteopetrosis. 2007 , 45, 753-62		10
169	Integrated pharmacokinetics and pharmacodynamics in drug development. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 713-37	6.2	48
168	Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. 2007 , 4, 711-21		71
167	Bisphosphonate action: revelations and deceptions from in vitro studies. 2007 , 96, 1872-8		19
166	Is there a role for bisphosphonates in chronic kidney disease?. 2007 , 20, 186-90		61
165	Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controlled trial. 2007 , 166, 1155-61		25
164	Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. <i>Osteoporosis International</i> , 2008 , 19, 773-779	5.3	41
163	Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. <i>Osteoporosis International</i> , 2008 , 19, 773-9	5.3	17
162	Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. <i>Journal of Bone and Mineral Research</i> , 2008 , 23, 1689-97	6.3	40

161	Comparative pharmacokinetics of two intravenous administration regimens of tiludronate in healthy adult horses and effects on the bone resorption marker CTX-1. 2008 , 31, 108-16		19
160	Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients. 2008 , 9, 1351-61		13
159	Bisphosphonates: how do they work?. 2008 , 22, 831-47		88
158	[New treatments in paediatric rheumatology: supportive measures]. <i>Archives De Pediatrie</i> , 2008 , 15, 870-28		1
157	Bisphosphonates: mechanism of action and role in clinical practice. 2008 , 83, 1032-45		829
156	Biodistribution and plasma protein binding of zoledronic acid. 2008 , 36, 2043-9		123
155	Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. <i>Postgraduate Medical Journal</i> , 2007 , 66, 853-8	2	14
154	Once-yearly intravenous zoledronate does not impair renal function in postmenopausal women. 2008 , 74, 557-9		3
153	Once-monthly risedronate for postmenopausal osteoporosis. 2010 , 1, 1-9		1
152	Adverse effects of bisphosphonates: implications for osteoporosis management. 2009 , 84, 632-7; quiz 638		281
151	Chronic kidney disease and bisphosphonate treatment: are prescribing guidelines unnecessarily restrictive?. <i>Postgraduate Medical Journal</i> , 2009 , 85, 327-30	2	6
150	In vitro determination of the release of alendronic acid from alendronate tablets of different brands during deglutition. 2009 , 98, 3575-81		6
149	L'aderenza alle terapie per l'osteoporosi: l'esempio dei bisfosfonati. 2009 , 119, 28-30		
148	A novel bioassay model to determine clinically significant bisphosphonate levels. 2009 , 17, 1553-7		42
147	Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease. 2009 , 118, 307-13		13
146	Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. <i>Osteoporosis International</i> , 2009 , 20, 291-7	5-3	84
145	Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. 2009 , 144, 667-76		109
144	Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. 2009 , 39, 304-16		36

143	Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. <i>Bone</i> , 2009 , 44, 423-7	4.7	31
142	Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis. <i>Bone</i> , 2009 , 44, 766-71	4.7	7
141	New generation pharmacotherapy in elderly multiple myeloma patients. 2009 , 10, 81-98		3
140	Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management. 2009 , 84, 632-638		184
139	Nanotechnological approaches against Chagas disease. <i>Advanced Drug Delivery Reviews</i> , 2010 , 62, 576-88	8.5	53
138	An in vitro assay to measure targeted drug delivery to bone mineral. <i>ChemMedChem</i> , 2010 , 5, 770-6	3.7	44
137	Solid-state forms of zoledronic acid: polymorphism in hydrates. 2010 , 99, 4962-72		19
136	A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis. 2010 , 3, 6		25
135	Short-term zoledronic acid reduces trabecular bone remodeling in dogs. 2010 , 118, 460-5		8
134	Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. 2010 , 2, 121-37		34
133	Is zoledronate toxic to human periodontal fibroblasts?. <i>Journal of Dental Research</i> , 2010 , 89, 40-5	8.1	53
132	Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA. 2010 , 26, 599-604		8
131	Bisphosphonate-related osteonecrosis of the jaws: a review of 34 cases and evaluation of risk. 2010 , 38, 255-9		62
130	Bone physiology, disease and treatment: towards disease system analysis in osteoporosis. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 89-118	6.2	39
129	Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. <i>Bone</i> , 2010 , 47, 169-80	4.7	212
128	Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. 2011 , 7, 447-56		187
127	Pharmacology of bisphosphonates. <i>Bone</i> , 2011 , 49, 42-9	4.7	148
126	Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. <i>Bone</i> , 2011 , 49, 706-9	4.7	20

125	Affinity of hydroxyapatite (001) and (010) surfaces to formic and alendronic acids: a quantum-mechanical and infrared study. 2011 , 13, 1099-111	26
124	Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates. 2011 , 5, 445-54	14
123	Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials. 2011 , 6, e26267	26
122	Use of bisphosphonates in the management of postmenopausal osteoporosis. 2011 , 1218, 15-32	16
121	Bone scans, bisphosphonates, and a lack of acute changes within the mandible. 2011 , 69, 114-9	8
120	Remarkable potential of the β -aminophosphonate/phosphinate structural motif in medicinal chemistry. 2011 , 54, 5955-80	412
119	Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women. 2011 , 32, 471-81	31
118	Pharmacodynamics of bisphosphonates in arthritis. 2011 , 4, 633-41	7
117	Bisphosphonate-modified gold nanoparticles: a useful vehicle to study the treatment of osteonecrosis of the femoral head. 2011 , 22, 035102	27
116	Renal complications from bisphosphonate treatment. 2012 , 6, 342-7	24
115	The elderly inflammatory bowel disease patient and osteoporosis. 2012 , 8, 31-42	2
114	A review of common oral pathology lesions, with a focus on periodontology and implantology. 2012 , 12, 254-62	5
113	Antiresorptive drugs (bisphosphonates), atypical fractures and rebound effect: new evidence of similitude. 2012 , 101, 231-42	16
112	Bisphosphonate-based strategies for bone tissue engineering and orthopedic implants. 2012 , 18, 323-40	62
111	Pamidronate. 392-396	
110	Pharmacology: Mechanism of Action of Bisphosphonates. 2012 , 13-22	
109	Lip ulceration associated with intravenous administration of zoledronic acid: report of a case. 2012 , 6, 275-8	6
108	Development of bone-targeted catalase derivatives for inhibition of bone metastasis of tumor cells in mice. 2012 , 101, 552-7	10

107	Osteoporose. 2013 , 46, 225-231		
106	Quantitation of zoledronic acid in murine bone by liquid chromatography coupled with tandem mass spectrometry. 2013 , 935, 54-60		15
105	Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?. 2013 , 11, 303		47
104	Comparison of serum Dkk1 (Dickkopf-1) and bone mineral density in patients on bisphosphonate treatment vs no treatment. 2013 , 16, 118-24		8
103	Drug carriers in osteoporosis: preparation, drug encapsulation and applications. <i>International Journal of Pharmaceutics</i> , 2013 , 445, 181-95	6.5	41
102	Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. 2013 , 36, 436-42		29
101	Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence. 2013 , 5, 199-209		21
100	Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 1738-50	6.3	6
99	Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatment. 2014 , 2014, 471035		40
98	Pharmacokinetic Characteristics of Ibandronate and Tolerability of DP-R206 (150 mg Ibandronate/24,000 IU Vitamin D3) Compared to the Ibandronate (150 mg) Monotherapy in Healthy Adults. 2014 , 22, 22		2
97	Phosphate group vibrational signatures of the osteoporosis drug alendronate. 2014 , 45, 801-806		11
96	Bisphosphonate-Associated Atypical Femur Fracture. 2014 , 44, 35-37		2
95	Alendronate in the Prevention of Collapse of the Femoral Head in Nontraumatic Osteonecrosis. 2014 , 265-271		1
94	Zoledronic Acid Elicits Proinflammatory Cytokine Profile in Osteolytic Prostate Cancer Cells. 2014 , 2014, 1-8		3
93	Platinum-Based Anticancer Agents. 2014 , 9-45		6
92	Effects of denosumab treatment and discontinuation on human growth plates. 2014 , 99, 891-7		50
91	A simple pharmacokinetic model of alendronate developed using plasma concentration and urine excretion data from healthy men. 2014 , 40, 1325-9		6
90	A network modeling approach for the spatial distribution and structure of bone mineral content. 2014 , 16, 478-87		1

89	Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonate-associated osteonecrosis of the jaw. 2015 , 13, 212		26
88	Zoledronic Acid-Induced Interface Dermatitis. 2015 , 37, 933-5		6
87	Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells. 2015 , 10, e0117021		17
86	Pharmacological Aspects of Antiresorptive Drugs: Bisphosphonates and Denosumab. 2015 , 1-15		
85	Effects of alendronate and pamidronate on apoptosis and cell proliferation in cultured primary human gingival fibroblasts. 2015 , 34, 1073-82		16
84	The biocompatibility of calcium phosphate cements containing alendronate-loaded PLGA microparticles in vitro. 2015 , 240, 1465-71		8
83	Encapsulation of alendronate sodium by nanoprecipitation and double emulsion: From preparation to in vitro studies. 2015 , 72, 24-33		32
82	Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis. 2016 , 22, 324-9		29
81	Prediction of denosumab effects on bone remodeling: A combined pharmacokinetics and finite element modeling. 2016 , 60, 492-504		19
80	Estimating the Time to Benefit for Preventive Drugs with the Statistical Process Control Method: An Example with Alendronate. 2016 , 33, 347-53		19
79	Hydrogen Sulfide and Carbon Monoxide Protect Gastric Mucosa Compromised by Mild Stress Against Alendronate Injury. 2016 , 61, 3176-3189		29
78	Neonatal transient hypophosphatemic hypercalciuric rickets in dizygous twins: A role for maternal alendronate therapy before pregnancy or antireflux medications?. <i>Archives De Pediatrie</i> , 2016 , 23, 957-62 ^{1.8}		6
77	Bisphosphonic acids as effective inhibitors of Mycobacterium tuberculosis glutamine synthetase. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2016 , 31, 931-8	5.6	12
76	Factors associated with atypical femoral fracture. <i>Rheumatology International</i> , 2016 , 36, 65-71	3.6	15
75	Comparison of treatment effects of teriparatide and the bisphosphonate risedronate in an aged, osteopenic, ovariectomized rat model under various clinical conditions. <i>Journal of Bone and Mineral Metabolism</i> , 2016 , 34, 303-14	2.9	12
74	Effect of hyperbaric oxygen therapy on tooth extraction sites in rats subjected to bisphosphonate therapy-histomorphometric and immunohistochemical analysis. <i>Clinical Oral Investigations</i> , 2017 , 21, 199-210	4.2	9
73	The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. <i>Cancer Treatment Reviews</i> , 2017 , 55, 71-82	14.4	36
72	Antiresorptives: Safety Concerns-Clinical Perspective. <i>Toxicologic Pathology</i> , 2017 , 45, 859-863	2.1	7

71	Antiresorptive treatment-associated ONJ. <i>European Journal of Cancer Care</i> , 2017 , 26, e12787	2.4	7
70	Thermodynamics (Solubility and Protonation Constants) of Risedronic Acid in Different Media and Temperatures (283.15-318.15 K). <i>Journal of Solution Chemistry</i> , 2017 , 46, 1903-1927	1.8	5
69	Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitizers of T cells for anticancer immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2017 , 114, 143-160	18.5	23
68	Utilization of chitosan-caged liposomes to push the boundaries of therapeutic delivery. <i>Carbohydrate Polymers</i> , 2017 , 157, 991-1012	10.3	38
67	Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors. <i>Molecules</i> , 2017 , 22,	4.8	19
66	Bone-targeting dendrimer for the delivery of methotrexate and treatment of bone metastasis. <i>Journal of Drug Targeting</i> , 2018 , 26, 818-828	5.4	17
65	Specific Inhibition of the Bifunctional Farnesyl/Geranylgeranyl Diphosphate Synthase in Malaria Parasites via a New Small-Molecule Binding Site. <i>Cell Chemical Biology</i> , 2018 , 25, 185-193.e5	8.2	19
64	Interactions between Clinically Used Bisphosphonates and Bone Mineral: from Coordination Chemistry to Biomedical Applications and Beyond. <i>ChemMedChem</i> , 2018 , 13, 289-302	3.7	15
63	A comprehensive overview on osteoporosis and its risk factors. <i>Therapeutics and Clinical Risk Management</i> , 2018 , 14, 2029-2049	2.9	88
62	Bisphosphonates for Postmenopausal Osteoporosis. 2018 , 545-552		1
61	Effects of anti-osteoporosis medications on total hip arthroplasty risks in osteoporotic patients with hip osteoarthritis in Taiwan: a nationwide cohort study. <i>Archives of Osteoporosis</i> , 2018 , 13, 107	2.9	5
60	Strong binding and fluorescence sensing of bisphosphonates by guanidinium-modified calix[5]arene. <i>Beilstein Journal of Organic Chemistry</i> , 2018 , 14, 1840-1845	2.5	12
59	Interleukin 17 enhances bone morphogenetic protein-2-induced ectopic bone formation. <i>Scientific Reports</i> , 2018 , 8, 7269	4.9	23
58	Medication-Related Osteonecrosis of the Jaws. <i>Journal of the National Cancer Institute Monographs</i> , 2019 , 2019,	4.8	9
57	In Vivo Evaluation of Isoprenoid Triazole Bisphosphonate Inhibitors of Geranylgeranyl Diphosphate Synthase: Impact of Olefin Stereochemistry on Toxicity and Biodistribution. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019 , 371, 327-338	4.7	8
56	Pharmacometrics and systems pharmacology for metabolic bone diseases. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1136-1146	3.8	8
55	Possible role for glucagon in the control of Paget's disease of bone. <i>Postgraduate Medical Journal</i> , 2019 , 95, 85-90	2	
54	A patent review of bisphosphonates in treating bone disease. <i>Expert Opinion on Therapeutic Patents</i> , 2019 , 29, 315-325	6.8	13

53	Inhibition of macrophage viability by bound and free bisphosphonates. <i>Acta Histochemica</i> , 2019 , 121, 400-406	2	6
52	Physiological concentrations of denosumab enhance osteogenic differentiation in human mesenchymal stem cells of the jaw bone. <i>Archives of Oral Biology</i> , 2019 , 101, 23-29	2.8	3
51	Predicting binding affinities of nitrogen-containing bisphosphonates on hydroxyapatite surface by molecular dynamics. <i>Chemical Physics Letters</i> , 2019 , 716, 83-92	2.5	9
50	Pharmacology of bisphosphonates. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1052-1062	3.8	59
49	Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1125-1135	3.8	5
48	Clinical Pharmacology of Bisphosphonates. 2020 , 579-589		1
47	Bone turnover markers. 2020 , 1801-1832		
46	Clinical and translational pharmacology of bisphosphonates. 2020 , 1671-1687		
45	A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer-Induced Osteolytic Bone Resorption. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 420-431	6.1	6
44	Establishment of a Disease-Drug Trial Model for Postmenopausal Osteoporosis: A Zoledronic Acid Case Study. <i>Journal of Clinical Pharmacology</i> , 2020 , 60 Suppl 2, S86-S102	2.9	1
43	Histologic evaluation of femoral nerve demyelinating and axonal neuropathy in Wistar rats due to alendronate intake: a randomised study. <i>Journal of Biological Research</i> , 2020 , 27, 2	2.4	0
42	Skeletal abnormalities secondary to antenatal etidronate treatment for suspected generalised arterial calcification of infancy. <i>Bone Reports</i> , 2020 , 12, 100280	2.6	2
41	Pamidronate: A model compound of the pharmacology of nitrogen-containing bisphosphonates; A Leiden historical perspective. <i>Bone</i> , 2020 , 134, 115244	4.7	5
40	Long-Term Response to a Bioactive Biphasic Biomaterial in the Femoral Neck of Osteoporotic Rats. <i>Tissue Engineering - Part A</i> , 2020 , 26, 1042-1051	3.9	5
39	Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. <i>Nature Reviews Endocrinology</i> , 2020 , 16, 437-447	15.2	78
38	Therapies for Preventing Bone Loss with Glucocorticoid Treatment. <i>Current Osteoporosis Reports</i> , 2021 , 19, 34-39	5.4	2
37	On the effect of antiresorptive drugs on the bone remodeling of the mandible after dental implantation: a mathematical model. <i>Scientific Reports</i> , 2021 , 11, 2792	4.9	3
36	New insights into the diagnosis and management of bone health in premature ovarian insufficiency. <i>Climacteric</i> , 2021 , 24, 481-490	3.1	1

35	Osteoporosis treatment with risedronate: a population pharmacokinetic model for the description of its absorption and low plasma levels. <i>Osteoporosis International</i> , 2021 , 32, 2313-2321	5.3	
34	Individualized Bone-Protective Management in Long-Term Cancer Survivors With Bone Metastases. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 1906-1913	6.3	1
33	Diffuse adverse cutaneous reactions induced by zoledronic acid administration: a case report : Eruptions cutanées diffuses induites par l'administration de l'acide zoledronique. <i>Osteoporosis International</i> , 2021 , 32, 2583-2586	5.3	1
32	Modulation of biopharmaceutical properties of acidic drugs using cationic counterions: A critical analysis of FDA-approved pharmaceutical salts. <i>International Journal of Pharmaceutics</i> , 2021 , 607, 120993	6.5	2
31	Antiresorptive-Type and Discontinuation-Timing Affect ONJ Burden. <i>Journal of Dental Research</i> , 2021 , 100, 746-753	8.1	7
30	Liposomes as multifaceted delivery system in the treatment of osteoporosis. <i>Expert Opinion on Drug Delivery</i> , 2021 , 18, 761-775	8	4
29	Bisphosphonates for Postmenopausal Osteoporosis. 412-419		2
28	Osteoporosis for the Female Patient. 2017 , 195-208		1
27	Silica-Based Polymeric Gels as Platforms for Delivery of Phosphonate Pharmaceuticals. <i>Gels Horizons: From Science To Smart Materials</i> , 2018 , 127-140		2
26	Inhibition of Farnesyl and Geranylgeranyl Diphosphate Synthases. <i>The Enzymes</i> , 2011 , 30, 301-319	2.3	5
25	Timing of anti-osteoporosis medications initiation after a hip fracture affects the risk of subsequent fracture: A nationwide cohort study. <i>Bone</i> , 2020 , 138, 115452	4.7	3
24	Bisphosphonates pathway. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 50-3	1.9	36
23	Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo. <i>Oncotarget</i> , 2016 , 7, 87373-87389	3.3	8
22	Bisphosphonates and Cancer: A Relationship Beyond the Antiresorptive Effects. <i>Mini-Reviews in Medicinal Chemistry</i> , 2019 , 19, 988-998	3.2	3
21	Osteoporosis Management with Focus on Spine. 2021 , 61-92		
20	Bisphosphonates in the Management of Osteoporosis. 2006 , 209-217		
19	Skeletal Demineralization. 2007 , 21-39		
18	Klinik der Perimenopause, der Postmenopause und des Seniums. 2009 , 521-559		1

17	Myeloma Bone Disease. 2014 , 211-223		
16	How Long to Treat with Bisphosphonates?. <i>Health</i> , 2015 , 07, 1615-1621	0.4	
15	Risque d'ostéoporose des maxillaires associé à un traitement par biphosphonates dans l'enfance. <i>Medecine Buccale Chirurgie Buccale</i> , 2016 , 22, 43-48		
14	Osteoporosis in Cardiopulmonary, Kidney and Liver Disorders. 2017 , 275-322		
13	A specific non-bisphosphonate inhibitor of the bifunctional farnesyl/geranylgeranyl diphosphate synthase in malaria parasites.		0
12	Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. <i>Therapeutics and Clinical Risk Management</i> , 2006 , 2, 3-18	2.9	11
11	Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2007 , 4, 30-6		4
10	Osteoporosis and gastrointestinal disease. <i>Gastroenterology and Hepatology</i> , 2010 , 6, 506-17	0.7	23
9	Assessment of a bone biopsy technique for measuring tiludronate in horses: a preliminary study. <i>Canadian Journal of Veterinary Research</i> , 2011 , 75, 128-33	0.5	2
8	Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. <i>Canadian Family Physician</i> , 2014 , 60, 324-33	0.9	82
7	Proximal Femur Responses to Sequential Therapy With Abaloparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis by 3D Modeling of Hip Dual-Energy X-Ray Absorptiometry (DXA).. <i>JBMR Plus</i> , 2022 , 6, e10612	3.9	0
6	Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2100311	2.2	1
5	Pharmacometrics: The Already-Present Future of Precision Pharmacology.		
4	Radiographic changes of mandibular cortical bone in bisphosphonate drug holiday. 2022 , 48, 219-224		2
3	Bone Health Management in the Continuum of Prostate Cancer Disease. 2022 , 14, 4305		1
2	Advancement in the Treatment of Osteoporosis and the Effects on Bone Healing. 2022 , 11, 7477		0
1	Withaferin A inhibits breast cancer-induced osteoclast differentiation.		0